EVALUATION OF CARDIOSPERMUMHALICACABUM LINN. ETHANOLIC EXTRACT FOR ANTIOXIDANT AND ANTICANCERACTIVITY

Main Article Content

M. Surendrakumar
M. Balaji
S. Navina
K. Swetha
T. TamilSelvan
N. Astalakshmi
B. Sudhakar

Keywords

Cardiospermum halicacabum, antioxidant (DPPH scavenging activity), anticanceractivity (MTT Assay), L929 and PC-3 cell line

Abstract

PlantclimbingCardiospermumhalicacabumLinn.Cardiospermumhalicacabumvar.and
Cardiospermum microcarpumare synonyms forCardiospermum halicacabumLinn. The lesserballoon vine, balloon plant, love in a puff, heart seed vine, and heart pea are other names for it. Itsgrowthtypeisaperennialherbaceousvinewithslender,downystemsthatclimbswithtendrilsupto 3m on a support. The monoecious flower species has both male and female flowers on the sameplant. In its native surroundings, this species can be found in grasslands, shrublands, forest margins,wastelands,andcultivatedareas. The herb is used to cure rheumatism, abdominal pain, orchitis,skindisorders,cough,andhyperthermiaintraditionalIndianmedicine.CardiospermumhalicacabumL. whole plant ethanolic extracts were tested for their ability to scavenge DPPH atdoses of 20µg, 40µg, 60µg, 80µg, and 100µg. The results suggest that 57µg is the half maximuminhibitoryconcentration(IC50).Cardiospermum halicacabumL. whole plant ethanolic extractswere tested for anticancer activity using the MTT assay at doses of 5µg, 25µg, 50µg, 75µg, and100µg.Cardiospermum halicacabumL., the sample given, exhibited mild to moderate cytotoxicityto L929 cell line, mild to severe cytotoxicity to PC-3 cells . As would be predicted, the controlrevealed no cytotoxicity. The results suggest the ethanolic extract possesses an cytotoxic propertywith an IC50 values of 75 µg for normal cell lines and IC50 value of 22 µg for prostate cancer celllines.Thus,wereachtheconclusion that the whole plant ethanolic extract ofCardiospermumhalicacabumL.is asuperiorcrude medicineofchoice forantioxidantand anticanceractivity.

Abstract 98 | PDF Downloads 0

References

1.RazaSA,HussainS,RiazH,MahmoodS.Review of beneficial and remedial aspects of
Cardiospermum halicacabum L. Afr J Pharmacol 2013;7 Suppl 48:.
2.SavithaG,VishnupriyaV,KrishnamohanS,GeethaRV.Analysisofphytochemicalconstituents
andantimicrobialpropertiesofCardiospermumhalicacabumLinn.DrugInventionToday.2018Sep 2;10.
3.RajasekaranA,KaliselvanV,SarathikumarN,KalaivaniM.Simultaneousestimationof
luteolin and apigenin in methanolic leaf extract of Cardiospermum halicacabum by HPLC. IntRes J Pharm 2013;4 Suppl 7:109-13
4.ManjuShreeS,AzamthullaM.AREVIEWOFCARDIOSPERMUMHALICACABUM
(SAPINDACEAE).
5.RazaSA,HussainS,RiazH,MahmoodS.Reviewofbeneficialandremedialaspectsof
Cardiospermum halicacabum L. Afr J Pharmacol 2013;7 Suppl 48:.
6.ShaikhSH,FarnazM,HenryJ,HamidA,Trendsintheuseofcomplementaryandalternative
medicinein Pakistan:a population basedsurvey. J. Altern.Compl, 2009;
7.15(5): 545-550.
8.Deepan T, Alekhya V, Saravanakumar P, Dhanaraju MD. Phytochemical and Anti-Microbial
Studies on the Leaves Extracts of Cardiospermum halicacabum Linn. Adv. Biol. Res., 2012;6(1): 14-18.
9.Bland JS (1995): Oxidants and antioxidants in clinical medicine: Past, present, and future. J
Nutr Environ Med 5: 255–280.
10.GerberM,Boutron-RuaultMC,HercbergS,RiboliE,ScalbertA,SiessMH(2002):Foodand
cancer: State of the art about the protective effect of fruits and vegetables. Bull Cancer 89:
293–312
11.Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE,
EthertonTD(2002):Bioactivecompoundsinfoods:Theirroleinthepreventionofcardiovasculardisease andcancer. AmJ Med113 (Suppl9B): 71S–88S
12.Oomah BD, Mazza G (1994): Flavanoids and antioxidant activities in buckwheat. J Agric Food
Chem 7: 1746–1750
13.Cao GH, Sofic E, Prior RL (1996): Antioxidant capacity of tea and vegetables. J Agric Food
Chem 44: 3426–3431.
14.BergmanM,VarshavskyL,GottliebHE,GrossmanS(2001):The antioxidant activity of
aqueousspinachextract:Chemicalidentificationofactivefractions.Phytochemistry58:143–152.
15.WangH,CaoGH,PriorRL(1996):Totalantioxidantcapacityoffruits.JAgricFoodChem44:
701–705.
16.DiplockA,CharleuxJ,Grozier-WilliG,KokK,RiceEvansC,RoberfroidM,StahlW,
Vina-Ribes J (1998): Functional food sciences and defence against reactive oxidative species.Br J Nutr 80: 77–82.
17.Halliwell B (1997): Antioxidants and human disease: A general introduction. Nutr Rev 55:44–
52.
18.SiegelABandZhuAX.Metabolicsyndromeandhepatocellularcarcinoma:twogrowing
epidemicswith a potential link. J Cancer 2009;115:5651-61.
19.Kushi LH, Doyle C and Mc Cullough M. American Cancer Society Guidelines on nutrition and
physicalactivityforcancerprevention:reducingtheriskofcancerwithhealthyfoodchoicesandphysical activity. CA CancerJ Clin 2012;62 (1):30-67.
20.Kinzler, Kenneth Vogelstein and Bert. The genetic basis of human cancer. J New York:Mc
Graw-Hill, Medical Pub 2002;005-009.
21.KuperH,BoffettaP,AdamiHO.Tobaccouseandcancercausation:associationbytumourtype.
J of Internal Medicine 2002;252 (3):206-24.
22.EllestadGA.Structuralandconformationalfeaturesrelevanttotheanti-tumoractivityof
calicheamiciny. J Chirality2011;23, 660-71.
23.Oyaizu M (1986): Studies on product of browning reaction prepared from glucose amine. Jpn J
Nutr44: 307–315,[CSA] [Crossref],[Web ofScience ®],[Google Scholar].
24.Huang DJ, Ou BX, Prior RL. The chemistry behind antioxidant capacity assays. J Agric Food
Chem 2005;53:1841-1856.
25.Zi X, Guo Y, Simoneau AR, et al. Expression of Frzb/secreted Frizzled-related protein 3, a
secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppressestumor growth and cellular invasiveness. Cancer Res. 2005;65(21):9762–9770.
26.SinghPR,PriyaES,Balakrishnan S, et al. Inhibition of cell survival and proliferation by
nimbolide in human androgen-independent prostate cancer (PC-3) cells: involvement of thePI3K/Aktpathway. Mol CellBiochem. 2017;427(1–2):69–79.
27.TaiS,SunY,SquiresJM,ZhangH,OhWK,LiangCZ,HuangJ.PC3isacellline
characteristicof prostaticsmall cellcarcinoma. The Prostate.2011 Nov;71(15):1668-79.
28.CooperbergMR,ParkS,CarrollPR.Prostate cancer 2004: Insights from national disease
registries.
29.Oncology (Williston Park) 2004;18:1239–1247. discussion 48–50, 56–58. [PubMed] [Google
Scholar]
30.26 Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res.
2009;1:148–162. [PMC free article] [PubMed] [Google Scholar]
31.HuangJ,WuC,diSant’AgnesePA,YaoJL,ChengL, Na Y. Function and molecular
mechanismsofneuroendocrinecellsinprostatecancer.AnalQuantCytolHistol.2007;29:128–138. [PubMed] [Google Scholar]
32.Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: Neuroendocrine
transdifferentiationofprostateadenocarcinomacells.EndocrRelatCancer.2007;14:531–547.
[PubMed] [Google Scholar]
33.VashchenkoN,AbrahamssonPA.Neuroendocrinedifferentiationinprostatecancer:
Implicationsfornewtreatmentmodalities. Eur Urol. 2005;47:147–155. [PubMed] [GoogleScholar]